CLINICAL_TRIALS
research
· 2026-03-25
Clinical Trial Update: Neutralizing Interleukin (IL)-6 [Phase 2]
Summary
A Phase 2 clinical trial evaluating a neutralizing interleukin-6 agent for major depressive disorder is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Major Depressive Disorder | Phase 2 | Status: RECRUITING